Provided by Tiger Trade Technology Pte. Ltd.

Sonnet BioTherapeutics Holdings, Inc.

1.26
-1.8400-59.35%
Post-market: 1.00-0.2600-20.63%17:09 EST
Volume:9.67M
Turnover:15.54M
Market Cap:8.92M
PE:-0.25
High:3.23
Open:3.16
Low:1.26
Close:3.10
52wk High:19.30
52wk Low:1.08
Shares:7.08M
Float Shares:6.23M
Volume Ratio:12.23
T/O Rate:155.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0074
EPS(LYR):-11.3504
ROE:-714.96%
ROA:-223.80%
PB:-2.93
PE(LYR):-0.11

Loading ...

Hyperliquid Strategies Inc and Sonnet Biotherapeutics Holdings, Inc. Announce Closing of Business Combination

THOMSON REUTERS
·
40 mins ago

Top Midday Decliners

MT Newswires Live
·
2 hours ago

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM

Reuters
·
Yesterday

BRIEF-Sonnet Biotherapeutics Holdings Announces Stockholder Approval Of Proposed Business Combination With Hyperliquid Strategies

Reuters
·
Yesterday

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

GlobeNewswire
·
Nov 18

Are XRP, SOL Done? HYPE Pumps 10% On $1 Billion Treasury Raise

Benzinga
·
Oct 23

Sonnet BioTherapeutics, Spanios collaborate on non-clinical study of SON-1010

TIPRANKS
·
Oct 15

Sonnet Biotherapeutics Holdings Inc. Held Annual Meeting of Stockholders

Reuters
·
Sep 30

Many crypto-treasury companies are trading for less than what their digital assets are worth. Is this a bargain or a big red flag?

Dow Jones
·
Sep 27

Sonnet to Present at the MedInvest Biotech & Pharma Conference

GlobeNewswire
·
Sep 19

Top Premarket Decliners

MT Newswires Live
·
Sep 15

Sonnet Biotherapeutics Holdings Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Aug 27

Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 14

Sonnet BioTherapeutics Q3 EPS $(0.95) Misses $(0.49) Estimate

Benzinga
·
Aug 14

Sonnet Releases Virtual Investor "What This Means" Segment

GlobeNewswire
·
Aug 11

Sonnet Biotherapeutics Holdings Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
Aug 09

Sonnet Biotherapeutics Expands Clinical Evaluation of Son-1010 Dose Escalation With Atezolizumab in Ovarian Cancer

THOMSON REUTERS
·
Aug 04

Sonnet Biotherapeutics Holdings Inc - Topline Data Show Strong Potential for Son-1010 Benefit

THOMSON REUTERS
·
Aug 04

Sonnet Biotherapeutics Holdings Inc - Top Line Readouts Expected in Q4 2025

THOMSON REUTERS
·
Aug 04

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

GlobeNewswire
·
Aug 04